Ampio Pharmaceuticals, Inc. (AMPE) Financial Statements (2024 and earlier)

Company Profile

Business Address 9800 MOUNT PYRAMID COURT, SUITE 400
ENGLEWOOD, CO 80112
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)

9/30/2023
MRQ
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments12,653,00033,892,00017,346,0006,532,0007,585,3928,220,469
Cash and cash equivalents12,653,00033,892,00017,346,0006,532,0007,585,3928,209,071
Short-term investments      11,398
Prepaid expense13,00068,00069,000531,000  
Deferred costs      
Derivative instruments and hedges, assets      12,000
Other undisclosed current assets663,0001,672,0001,078,0001,187,000413,280210,417
Total current assets:13,329,00035,632,00018,493,0008,250,0007,998,6728,442,886
Noncurrent Assets
Operating lease, right-of-use asset 75,000629,000824,0001,003,000
Property, plant and equipment 184,0002,564,0003,561,0004,748,0005,997,5826,837,861
Deposits noncurrent assets     33,85633,856
Total noncurrent assets: 259,0003,193,0004,385,0005,751,0006,031,4386,871,717
TOTAL ASSETS:13,588,00038,825,00022,878,00014,001,00014,030,11015,314,603
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:852,0004,811,0001,550,0004,025,0001,324,6512,785,529
Employee-related liabilities389,000 72,000  
Accounts payable97,000427,000186,000151,000  
Accrued liabilities334,000731,000420,000368,000  
Other undisclosed accounts payable and accrued liabilities421,0003,264,000944,0003,434,0001,324,6512,785,529
Debt   284,000259,000  
Deferred rent credit     59,579
Deferred revenue and credits59,579
Other undisclosed current liabilities340,000311,000   1,033,261
Total current liabilities:1,192,0005,122,0001,834,0004,284,0001,384,2303,878,369
Noncurrent Liabilities
Long-term debt and lease obligation:  614,000925,0001,210,000  
Liabilities, other than long-term debt 607,0005,805,0002,607,0002,064,0007,409,78445,613,119
Deferred revenue and credits537,364
Deferred rent credit     476,753
Asset retirement obligations 289,000     
Operating lease, liability 274,000614,000925,0001,210,000
Derivative instruments and hedges, liabilities 44,0005,805,0002,607,0002,064,0006,933,03145,075,755
Total noncurrent liabilities: 607,0006,419,0003,532,0003,274,0007,409,78445,613,119
Total liabilities:1,799,00011,541,0005,366,0007,558,0008,794,01449,491,488
Equity
Equity, attributable to parent, including:11,789,00027,284,00017,512,0006,443,0005,236,09634,200,000
Common stock 2,00023,00019,00016,00011,0948,006
Additional paid in capital245,726,000244,863,000218,020,000191,060,000176,227,510170,803,783
Accumulated deficit(233,939,000)(217,602,000)(200,527,000)(184,633,000)(171,002,508)(204,988,674)
Other undisclosed equity, attributable to parent      68,376,885
Other undisclosed equity      (68,376,885)
Total equity:11,789,00027,284,00017,512,0006,443,0005,236,096(34,176,885)
TOTAL LIABILITIES AND EQUITY:13,588,00038,825,00022,878,00014,001,00014,030,11015,314,603

Income Statement (P&L) (USD)

9/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Operating expenses(22,318,000)(20,571,000)(15,834,000)(18,576,000)(11,183,962)(15,564,956)
Other operating income, net     45,170,128 
Operating income (loss):(22,318,000)(20,571,000)(15,834,000)(18,576,000)33,986,166(15,564,956)
Nonoperating income (expense)5,981,0003,496,000(60,000)4,946,000 (36,326,989)
Investment income, nonoperating5,761,0003,492,000(543,000)4,869,000 (36,218,832)
Income (loss) from continuing operations:(16,337,000)(17,075,000)(15,894,000)(13,630,000)33,986,166(51,891,945)
Income (loss) before gain (loss) on sale of properties:(17,075,000)(15,894,000)(13,630,000)33,986,166(51,891,945)
Net income (loss) attributable to parent:(16,337,000)(17,075,000)(15,894,000)(13,630,000)33,986,166(51,891,945)
Preferred stock dividends and other adjustments  (3,492,000) (4,869,065)  
Other undisclosed net loss available to common stockholders, basic(5,761,000)     
Net income (loss) available to common stockholders, diluted:(22,098,000)(20,567,000)(15,894,000)(18,499,065)33,986,166(51,891,945)

Comprehensive Income (USD)

9/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Net income (loss):(16,337,000)(17,075,000)(15,894,000)(13,630,000)33,986,166(51,891,945)
Comprehensive income (loss), net of tax, attributable to parent:(16,337,000)(17,075,000)(15,894,000)(13,630,000)33,986,166(51,891,945)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: